The large number of new emerging designer drugs and the need to detect not only the parent analyte but their metabolites poses a big challenge in forensic screening. Ion mobility combined with HRES mass spectrometry allows for the identification and characterization of known as well as unknown analytes extending the scope to address these challenges.